In KEYNOTE-054, 1,019 patients with completely resected high-risk stage III melanoma were 1:1 randomised to adjuvant therapy with pembrolizumab (200 mg) or placebo every 3 weeks for a total of 18 doses (∼1 year) or until disease recurrence or unacceptable toxicity. The primary endpoint, recurrence-free survival (RFS), was in favour of pembrolizumab (HR 0.56 [1].
Updated results at 3.5 years of median follow-up showed that, compared with placebo, pembrolizumab significantly prolonged distant metastasis-free survival (DMFS) both in the overall population (65.3% vs 49.4%; HR 0.60; P<0.001) and in the PD-L1-positive tumour population (n=853; 66.7% vs 51.6%; HR 0.61; P<0.0001). Most benefit of adjuvant pembrolizumab was observed in patients with BRAF-mutated melanoma (64% vs 43%; HR 0.53) [2].
In CheckMate-238, 906 patients with completely resected high-risk, stage III/IV melanoma were 1:1 randomised to adjuvant therapy with nivolumab (3 mg/kg every 2 weeks) or ipilimumab (10 mg/kg every 3 weeks for 4 doses, every 12 weeks thereafter) for ≤1 year or until disease recurrence/unacceptable toxicity. At a minimum follow-up of 24 months, recurrence-free survival (RFS) was significantly longer for nivolumab versus ipilimumab (HR 0.66; P<0.0001) [3].
Now, at 48 months follow-up, median RFS was still in favour of nivolumab (52.4 vs 24.1 months; HR 0.71; P=0.003); RFS rate at 48 months was 52% and 41%, respectively [4]. DMFS also favoured nivolumab (median not reached vs 52.9 months; HR 0.79; P=0.045); DMSF rate at 48 months was 59% and 53%, respectively. However, at 48 months, overall survival rates were comparable (78% vs 77%, respectively; HR 0.87; P=0.3148).
- Eggermont AMM, et al. J Clin Oncol 2020;Sep 18;JCO2002110.
- Eggermont AMM, et al. Pembrolizumab versus placebo after complete resection of high-risk stage III melanoma: Final results regarding distant metastasis-free survival from the EORTC 1325-MG/Keynote 054 double-blinded phase III trial. ESMO 2020 Virtual Meeting, abstract LBA46.
- Weber JS, et al. J Clin Oncol 36, 2018 (suppl; abstr 9502)
- Weber JS, et al. Adjuvant nivolumab (NIVO) vs ipilimumab (IPI) in resected stage III/IV melanoma: 4-y recurrence-free and overall survival (OS) results from CheckMate 238. ESMO 2020 Virtual Meeting, abstract 1076O.
Posted on
Previous Article
« Immuno-combination therapy in metastatic melanoma Next Article
Consolidation ipilimumab and nivolumab in limited stage SCLC »
« Immuno-combination therapy in metastatic melanoma Next Article
Consolidation ipilimumab and nivolumab in limited stage SCLC »
Table of Contents: ESMO 2020
Featured articles
COVID-19 and Cancer
Breast Cancer
Gastrointestinal Cancers
Lung Cancer
Melanoma
Genitourinary Cancers
Bladder cancer risk and early detection
Gynaecological Cancers
Basic Science
Related Articles
November 25, 2020
Treatment of recurrent ovarian cancer

November 25, 2020
Second-line sacituzumab govitecan improves survival in metastatic TNBC
© 2021 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy